Unveiling the Role of the CCL24-CCR3 Axis in Myocardial Fibrosis: The Critical Contribution of Rat Anti-Mouse CD193 Antibodies

1. Concept

Myocardial fibrosis stands as a key pathological process driving the progression of various heart diseases to heart failure. It is characterized by the excessive activation of cardiac fibroblasts, which secrete large quantities of extracellular matrix proteins, ultimately leading to myocardial stiffness and impaired cardiac function. The heart harbors a substantial population of resident macrophages that play multifaceted roles in maintaining tissue homeostasis, responding to injury, and mediating repair processes. Abnormal crosstalk between immune cells and resident cardiac cells (e.g., fibroblasts, cardiomyocytes) is a well-recognized driver of fibrosis. The chemokine CCL24 and its exclusive receptor CCR3 (also known as CD193) have emerged as a critical signaling axis connecting immune cells and fibroblasts in the context of cardiac pathology. To dissect the in vivo function of this axis, the rat anti-mouse CD193 antibody—specifically recognizing the mouse CCR3 protein—has become an indispensable tool for researchers, enabling precise detection and functional manipulation of CCR3-mediated signaling.

2. Research Frontiers

2.1 The Role of Cardiac Macrophages in Myocardial Fibrosis

Cardiac resident macrophages are key players in the complex network of cellular interactions that regulate myocardial fibrosis. Under pathological stimuli such as pressure overload, these macrophages secrete specific factors that modulate the activity of cardiac fibroblasts. However, the precise molecular mechanisms by which cardiac resident macrophages regulate fibroblast activation have long remained elusive. The identification of the CCL24-CCR3 axis as a critical bridge between immune cells and fibroblasts has shed new light on this process. This axis provides a direct communication pathway, allowing cardiac resident macrophages to exert targeted effects on fibroblasts, thereby driving or modulating fibrosis. The rat anti-mouse CD193 antibody facilitates the study of this interaction by enabling the specific detection and targeting of CCR3, the downstream receptor of CCL24, on cardiac fibroblasts.

2.2 Cardiac Resident Macrophages: The Primary Source of CCL24

A fundamental question in understanding the CCL24-CCR3 axis is identifying the cellular source of CCL24 in the diseased heart. Through the analysis of published single-cell transcriptomic datasets and in situ hybridization of cardiac tissue, researchers found that Ccl24 mRNA expression is specifically enriched in cardiac resident macrophages, with negligible expression in other cardiac cell types such as fibroblasts and cardiomyocytes. Lineage tracing techniques further confirmed that CCL24 protein is specifically produced by cardiac resident macrophages at the protein level. Bone marrow chimera experiments ruled out monocyte-derived macrophages as the primary source of CCL24, solidifying cardiac resident macrophages as the key producers. Mechanistically, the synergistic effects of the cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) were identified as upstream signals that stimulate CCL24 production in cardiac resident macrophages. These findings establish cardiac resident macrophages as the primary cellular source of CCL24 during the early stages of pathological cardiac remodeling. While this study focused on identifying CCL24 sources, the rat anti-mouse CD193 antibody can be combined with macrophage marker antibodies for multicolor flow cytometry to simultaneously identify CCR3-expressing cells, offering a versatile tool for comprehensive cellular analysis.

2.3 Activation of Cardiac Fibroblasts by CCL24 via CCR3

CCR3 is the sole known receptor for CCL24, and flow cytometry analysis revealed that CCR3 protein is most abundantly expressed on fibroblasts among all cardiac cell types. The binding of CCL24 (secreted by cardiac resident macrophages) to CCR3 on fibroblasts triggers a cascade of downstream activation events. In vitro experiments demonstrated that stimulation of primary cardiac fibroblasts with recombinant CCL24 significantly promotes their proliferation (evidenced by increased Ki67-positive cells) and transformation into activated myofibroblasts (marked by upregulated α-smooth muscle actin expression). Additionally, CCL24 stimulation induces fibroblasts to secrete transforming growth factor-β (TGF-β), a classic pro-fibrotic factor that amplifies the fibrotic response through autocrine and paracrine mechanisms. Pretreatment with CCR3-selective antagonists or blocking antibodies completely abrogated CCL24-induced fibroblast activation and collagen I expression, confirming that this process is strictly dependent on the CCL24-CCR3 interaction. The rat anti-mouse CD193 antibody is critical in these functional validation experiments: it can be used in flow cytometry to quantify CCR3 expression on fibroblasts or as a blocking agent to directly interfere with CCL24-CCR3 binding in vitro, allowing researchers to observe the effects on fibroblast activation phenotypes.

2.4 Targeting CCR3 to Inhibit Myocardial Fibrosis and Improve Cardiac Function In Vivo

To validate the pathophysiological significance of the CCL24-CCR3 axis, multiple in vivo intervention strategies were employed. In pressure overload-induced mouse models, systemic knockout of CCL24 or short-term treatment with CCL24-neutralizing antibodies significantly improved cardiac systolic function and reduced myocardial interstitial fibrosis. Similarly, in vivo administration of small-molecule CCR3 antagonists achieved protective effects on cardiac function and reduced collagen deposition. The most direct evidence came from cell-specific gene knockout models: tamoxifen-induced, fibroblast-specific CCR3 knockout mice showed significantly reduced cardiac fibrosis and better-maintained cardiac function under pressure overload, without widespread changes in cardiac immune cell infiltration. These in vivo experiments strongly demonstrate that the CCL24-CCR3 axis is a key pathway driving pressure overload-induced myocardial fibrosis, primarily through the direct activation of cardiac fibroblasts rather than the modulation of systemic or local inflammatory responses. The rat anti-mouse CD193 antibody plays a supporting role in these in vivo studies by enabling the monitoring of CCR3 knockout efficiency in fibroblasts and the analysis of CCR3 expression changes across different cell subsets in treated cardiac tissues.

3. Research Significance

Investigating the role of the CCL24-CCR3 axis in myocardial fibrosis holds profound significance for both basic cardiac research and translational medicine:

• Basic research value: It clarifies the precise cellular and molecular mechanisms underlying macrophage-fibroblast crosstalk in the diseased heart, enhancing our understanding of the complex regulatory networks that drive myocardial fibrosis. This research provides new insights into the functional specialization of cardiac resident macrophages and their role in pathological cardiac remodeling.
• Translational research value: It identifies the CCL24-CCR3 axis as a promising therapeutic target for myocardial fibrosis and heart failure. The demonstration that targeting CCR3 (either through genetic knockout, small-molecule antagonists, or blocking antibodies) can inhibit fibrosis and improve cardiac function provides a strong rationale for the development of novel therapies. Additionally, the CCL24-CCR3 axis may serve as a potential biomarker for assessing disease progression or therapeutic response in patients with heart disease.

4. Related Mechanisms, Research Methods, and Product Applications

4.1 Core Mechanisms of the CCL24-CCR3 Axis in Myocardial Fibrosis

The CCL24-CCR3 axis drives myocardial fibrosis through a well-defined signaling cascade:

1. Initiation: Pressure overload or other pathological stimuli induce the production of IL-4 and IL-10 in the heart.
2. CCL24 secretion: IL-4 and IL-10 synergistically stimulate cardiac resident macrophages to secrete the chemokine CCL24.
3. Receptor binding: CCL24 binds to its exclusive receptor CCR3 (CD193) expressed on the surface of cardiac fibroblasts.
4. Fibroblast activation: CCR3 ligation activates downstream signaling pathways (e.g., PI3K/Akt), promoting fibroblast proliferation, transformation into myofibroblasts, and secretion of pro-fibrotic factors (e.g., TGF-β1, collagen I, αSMA).
5. Fibrosis amplification: TGF-β1 further amplifies the fibrotic response by autocrine and paracrine stimulation of additional fibroblasts, leading to excessive extracellular matrix deposition and myocardial fibrosis.

4.2 Key Research Methods

The study of the CCL24-CCR3 axis in myocardial fibrosis integrates multiple advanced research methods, with the rat anti-mouse CD193 antibody serving as a core tool:

• Single-cell transcriptomics and in situ hybridization: To identify the cellular source of CCL24 in the heart.
• Lineage tracing and bone marrow chimera experiments: To confirm that cardiac resident macrophages are the primary producers of CCL24.
• Flow cytometry: Using the rat anti-mouse CD193 antibody to quantify CCR3 expression on cardiac fibroblasts and other cell types.
• In vitro fibroblast stimulation assays: To assess the effects of CCL24 on fibroblast proliferation, activation, and pro-fibrotic factor secretion, with the CD193 antibody used for blocking experiments.
• In vivo intervention models: Including systemic CCL24 knockout, CCL24-neutralizing antibodies, small-molecule CCR3 antagonists, and fibroblast-specific CCR3 knockout, to validate the role of the axis in myocardial fibrosis.
• Cardiac function assessment and histological analysis: To evaluate the effects of interventions on cardiac function and fibrosis severity.

4.3 Product Applications: ANT BIO PTE. LTD.’s Rat Anti-Mouse CD193 Antibody

ANT BIO PTE. LTD.’s STARTER brand offers the “Rat Anti-Mouse CD193 Antibody (S-R699)” (Catalog No.: S0B5225)—a high-performance research tool designed for the detection and functional study of mouse CCR3 (CD193). This antibody is produced using premium rat monoclonal antibody technology, ensuring high specificity, affinity, and stability.

Core Product Advantages

• High specificity and precise cell subset identification: Specifically recognizes mouse CD193 (CCR3), which is primarily expressed on eosinophils, basophils, certain Th2 cells, mast cells, microglia, and cardiac fibroblasts. Enables precise identification and enrichment of these specific cell populations.
• Excellent affinity and detection performance: Delivers bright and stable fluorescence signals in flow cytometry (FACS), facilitating clear distinction between positive and negative populations in complex cell suspensions. Achieves accurate membrane staining in immunohistochemistry (IHC) and immunofluorescence (IF) applications, ideal for assessing the infiltration and distribution of CCR3-expressing cells in tissues.
• Rigorous quality control and batch consistency: Undergoes strict manufacturing controls to ensure consistent antibody concentration, titer, and specificity across batches. Supports long-term research and multicenter collaborations with reproducible and comparable data.

Key Research Applications

• Cardiovascular research: Study the role of the CCL24-CCR3 axis in myocardial fibrosis, cardiac remodeling, and heart failure. Useful for flow cytometry analysis of CCR3 expression on cardiac fibroblasts and blocking experiments to interfere with CCL24-CCR3 signaling.
• Allergic disease research: Investigate effector cell recruitment and activation in asthma, allergic rhinitis, and atopic dermatitis—diseases where CCR3-expressing eosinophils and basophils play key roles.
• Parasitic infection immunology: Analyze eosinophil activation and migration in parasitic infection models, particularly helminth infections.
• Th2 immune response analysis: Study the function of CCR3-expressing Th2 cells in allergies and autoimmune diseases.
• Neuroinflammation research: Explore the role of CCR3-expressing microglia in neurodegenerative diseases and central nervous system inflammation.
• Chemokine signaling studies: Investigate CCL11 (Eotaxin-1) and other chemokine-mediated cell migration and signal transduction via CCR3.

ANT BIO PTE. LTD. provides comprehensive technical support for this product, including detailed technical parameters, recommended concentrations, compatible sample types (e.g., peripheral blood, bone marrow, cardiac tissue, lung tissue), and suggestions for multicolor flow cytometry panel combinations. Our expert technical team is available for consultation to ensure successful research outcomes.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative research tools and solutions. As a leader in the field of life science reagents, we offer a comprehensive portfolio of products under three sub-brands: Absin (focused on general reagents and kits), Starter (specialized in antibodies), and UA (dedicated to recombinant proteins).

Our commitment to excellence is underpinned by advanced development platforms—including recombinant rabbit monoclonal antibody platforms, recombinant mouse monoclonal antibody platforms, rapid mouse monoclonal antibody platforms, recombinant protein expression platforms (E. coli, CHO, HEK293, Insect Cells), One-Step ELISA Platforms, and PTM Pan-Modification Antibody Platforms—as well as rigorous quality control systems. We have successfully obtained international certifications such as EU 98/79/EC, ISO9001, and ISO13485, ensuring that our products meet the highest global standards.

Our mission is to accelerate scientific discovery, facilitate translational research, and contribute to the development of novel therapies for human health. By partnering with researchers in academia and biopharmaceutical companies worldwide, we strive to be a trusted collaborator in advancing life science research and addressing unmet medical needs.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.